Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SRx Health Solutions (SRXH) Common Equity (2016 - 2025)

SRx Health Solutions' Common Equity history spans 15 years, with the latest figure at $407000.0 for Q3 2025.

  • For Q3 2025, Common Equity rose 100.74% year-over-year to $407000.0; the TTM value through Sep 2025 reached $407000.0, up 100.74%, while the annual FY2025 figure was $407000.0, N/A changed from the prior year.
  • Common Equity reached $407000.0 in Q3 2025 per SRXH's latest filing, up from -$45.9 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $62.7 million in Q3 2021 to a low of -$63.7 million in Q4 2024.
  • Average Common Equity over 5 years is $5.4 million, with a median of $8.0 million recorded in 2025.
  • Peak YoY movement for Common Equity: crashed 2260.57% in 2024, then surged 628.64% in 2025.
  • A 5-year view of Common Equity shows it stood at $57.9 million in 2021, then plummeted by 62.8% to $21.5 million in 2022, then tumbled by 86.31% to $2.9 million in 2023, then plummeted by 2260.57% to -$63.7 million in 2024, then skyrocketed by 100.64% to $407000.0 in 2025.
  • Per Business Quant, the three most recent readings for SRXH's Common Equity are $407000.0 (Q3 2025), -$45.9 million (Q2 2025), and $8.0 million (Q1 2025).